Real-Life Study in Diabetic Macular Edema

Kocaeli University854 enrolled

Overview

The goal of this study is to evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in diabetic macular edema (DME) patients.

The study included patients who were being observed in the retina departments of 8 tertiary hospitals in the Northern Marmara Region of Turkey (Istanbul's Asian Side, Kocaeli, and Sakarya). The records of DME patients treated with an anti-VEGF agent between January 2015 and December 2018 were reviewed.

Study Type

OBSERVATIONAL

Enrollment

854

Conditions

Diabetic Macular Edema

Interventions

Retrospective studyOTHER

Retrospective study

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetic macular edema treated with intravitreal anti-VEGF injection * Having at least 4 or more annual examination visits Exclusion Criteria: * Phacoemulsification surgery in the last 1 month * PRFK / grid / focal / micropulse in the last 4 months * Previous intraocular surgery (excluding PPV and phacoemulsification)

Locations (10)

Kocaeli University School of Medicine

Kocaeli, None Selected, Turkey (Türkiye)

Marmara University School of Medicine

Istanbul, Turkey (Türkiye)

Memorial Şişli Hospital

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Visit and Intravitreal Injection Numbers

The primary outcomes were changes in best-corrected visual acuity and central macular thickness in the first year and frequency of visits and intravitreal anti-VEGF injections.

Time frame: First year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.